10-Q quarterly report · filed Nov 3, 2026

Vertex Pharmaceuticals (VRTX) Q3 2026 10-Q Quarterly Report

Short answer

Vertex Pharmaceuticals (VRTX) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3.4B (up 11.8% year over year) with net income of $654M.

Q3 2026 key financials · XBRL

Revenue
$3.4B
+11.8% YoY · +3.2% QoQ
Net income
$654M
−39.6% YoY · −40.6% QoQ
Operating margin
20.7%
EPS (diluted)
$2.57
−38.8% YoY · −40.4% QoQ

Source: XBRL data from the Vertex Pharmaceuticals (VRTX) Q3 2026 10-Q on SEC EDGAR. USD.

Vertex Pharmaceuticals Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $3,440.8M, up 12% YoY from $3,076.4M
  • Cost-of-sales margin 15.3% vs 13.5% YoY; total costs and expenses $2,727.9M, up 44%
  • Best product: ALYFTREK revenue $705.8M, up 186%; weakest: TRIKAFTA/KAFTRIO $2,436.9M, down 8%
  • Cash, equivalents and securities $9,821.2M, down 20% from $12,320.4M; nine-month operating cash flow $3,196.6M
  • Crinetics acquisition consumed $9.1B net cash; $4.5B term loan increased future interest expense and debt repayments through 2029

Risk Factors

  • Newly added risk: Crinetics integration, including potential failure to retain key employees or realize synergies
  • Most materially updated risk: PALSONIFY and atumelnant may miss expected commercial performance or development timelines
  • Regulatory risk: povetacicept accelerated-approval review carries a November 30, 2026 PDUFA target action date
  • Operational risk: Integration activities could disrupt ongoing business and divert management attention
  • Financial risk: Crinetics acquisition benefits depend on future revenues from PALSONIFY and atumelnant

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Vertex Pharmaceuticals quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.